Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New chemotherapy treatment for advanced retinoblastoma in Tanzania
ISRCTN17864800Phase 2Recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of topotecan, cyclophosphamide, vincristine, etoposide and carboplatin in retinoblastoma (Rb) (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Time to survival from randomization. Started Dec 2025; status: recruiting.
02
Drugs
topotecancyclophosphamidevincristineetoposidecarboplatin
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on ISRCTN17864800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17864800.